Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Contribution of Lipid Droplets to the pathogenesis and chemoresistance of Acute Myeloid Leukemia

Project description

The role of lipid droplets in acute myeloid leukaemia

Acute myeloid leukaemia (AML) is high-risk cancer that starts in the differentiation-defective blood-forming cells of the bone marrow (BM). The poor response to treatment is associated with leukaemia – BM stroma interaction. Recent studies identified the cytosolic fat storage organelles, lipid droplets (LDs), as regulators of lipid metabolism and signalling in cells under stress conditions, including chemotherapy. The inhibition of LDs was shown as more effective than the standard-of-care chemotherapy in impairing AML cell proliferation. Funded by the Marie Skłodowska-Curie Actions programme, the ALERT project aims to characterise the LDs in AML and investigate their involvement with the BM stroma in the progression and refractoriness of AML.

Objective

Acute Myeloid Leukemia (AML) results from the uncontrolled expansion of differentiation-defective hematopoietic stem/progenitor cells or immature myeloid cells (blasts) in the bone marrow (BM). AML remains a high-risk disease mainly due to treatment refractoriness which is dependent on leukemia-BM stroma interactions. Unfortunately, treatments have only experienced minor developments over the last decades. On the other hand, emerging evidence in cancer metabolism has identified Lipid Droplets (LDs, cytosolic fat storage organelles) as key regulators of lipid metabolism and signalling in cells exposed to stress such as hypoxia, chemotherapy, and nutrient deprivation. However, the precise role of LDs in the pathogenesis and chemoresistance of AML remains poorly investigated. Here, we aim to i) characterize the accumulation and role of LDs in AML, ii) assess the functional impact of blasts- and BM stroma-LDs on AML pathogenesis and chemoresistance, and iii) investigate the involvement of LDs in the progression and refractoriness of AML. Cutting-edge in vitro (AML primary cells, BM-stroma cells) and in vivo assays (patient-derived xenografts) will be used to provide evidence of LDs as a key player in leukemogenesis. Our project is based on solid preliminary single cell-RNA sequencing data indicating that LDs are highly accumulated in AML blasts, and that inhibition of LDs is more effective than the standard-of-care chemotherapy in impairing AML cell proliferation.

Our proposal represents an innovative approach achievable thanks to the complementary knowledge and expertise of two top-notch laboratories in acute leukemia (supervisor) and LDs (collaborator). Results from this study will open new avenues to explore the therapeutic opportunity of LD inhibitors as anti-leukemic co-adjuvant.

This fellowship will enable me to acquire transformational knowledge in leukemia metabolism and will constitute a major first step towards initiating my independent academic career.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-MSCA-2021-PF-01

See all projects funded under this call

Coordinator

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 226 441,20
Address
CARRETERA DE CAN RUTI CAMI DE LES ESCOLES S/N
08916 Badalona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Partners (1)

My booklet 0 0